Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd.
No insider data available
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2023-03-31 | 2022-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|
Assets Current | |||||||
Cash And Cash Equivalents At Carrying Value | 11 | 14 | |||||
Restricted Cash Current | 0 | 0 | |||||
Other Receivables Net Current | - | 0 | |||||
Prepaid Expense Current | 0 | - | |||||
Assets Current | 11 | 14 | |||||
Non Current Assets | |||||||
Property Plant And Equipment Net | 11 | 11 | |||||
Operating Lease Right Of Use Asset | 1 | 1 | |||||
Assets Noncurrent | 12 | 13 | |||||
Assets | 23 | 27 | |||||
Liabilities Current | |||||||
Accounts Payable Trade Current | 1 | 1 | |||||
Short Term Borrowings | - | 0 | |||||
Accounts Payable And Other Accrued Liabilities Cur… | - | 1 | |||||
Operating Lease Liability | 0 | - | |||||
Other Accounts Payable And Accrued Liabilities | 1 | - | |||||
Liabilities Current | 3 | 2 | |||||
Non Current Liabilities | |||||||
Derivative Liabilities | 3 | 5 | |||||
Other Loans Payable Long Term | 22 | 20 | |||||
Operating Lease Liability Noncurrent | 1 | 1 | |||||
Liabilities Noncurrent | 26 | 26 | |||||
Shareholders Equity Defic… | |||||||
Stockholders Equity | |||||||
Additional Paid In Capital | 116 | 116 | |||||
Retained Earnings Accumulated Deficit | -119 | -116 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | -2 | -2 | |||||
Stockholders Equity | -5 | -2 | |||||
Liabilities And Stockholders Equity | 23 | 27 | |||||
Common Stock Shares Authorized | 5 | 5 | |||||
Common Stock Shares Issued | 0 | 0 | |||||
Shares Outstanding | 0 | 0 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|
| 2023 | -26.15% | -24.51% | -24.51% | - | - | - |
| 2022 | - | - | - | -12.09% | -37.21% | -35.81% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Scinai Immunotherapeutics Ltd. (SCNI) — SEC Financial Statements & Analysis
Scinai Immunotherapeutics Ltd. (SCNI) is a biological products, (no diagnostic substances) company, incorporated in L3. Scinai Immunotherapeutics Ltd. trades on Nasdaq as: SCNI. Based on its latest SEC filing (Form 10-Q, period ending 2023-03-31), Scinai Immunotherapeutics Ltd. reported a Debt-to-Equity ratio of -5.84x, a Price-to-Book (P/B) ratio of -14.54x (TTM), at a market cap of $69.94M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- -5.84x
- P/B TTM
- -14.54x
- Market Cap
- $69.94M
Data as of 2023-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Scinai Immunotherapeutics Ltd. in?
Scinai Immunotherapeutics Ltd. (SCNI) operates in the Biological Products, (No Diagnostic Substances) industry.
What is SCNI's market cap?
Scinai Immunotherapeutics Ltd. (SCNI) has a market capitalization of $69.94M as of 2023-03-31.
What exchange does SCNI trade on?
Scinai Immunotherapeutics Ltd. (SCNI) trades on the Nasdaq.
Where is Scinai Immunotherapeutics Ltd. incorporated?
Scinai Immunotherapeutics Ltd. is incorporated in Israel.